Abstract: A promoter activation sequence that allows for stable and efficient expression of a DNA of interest in a mammalian cell is provided. The promoter activation sequence has a nucleotide sequence represented by SEQ ID NO: 1, or a nucleotide sequence of 850 or more in a nucleotide sequence having 85% or higher sequence identity thereto. Also disclosed are an expression vector having the promoter activation sequence, a promoter, and a DNA of interest, a mammalian cell and a mammal including the expression vector.

Abstract: Provided is a method for producing a human artificial chromosome vector with high safety by using a human cell. The method for producing a human cell comprising a human artificial chromosome vector comprises: substantially eliminating endogenous genes of long-arm and short-arm in a disomic human cell containing a pair of the homologous human chromosomes or a trisomic human cell containing trisomy of the homologous human chromosomes, from one of two chromosomes of the disomy or one or two of three chromosomes of the trisomy, thereby producing a cell population containing a human cell containing a human artificial chromosome vector comprising long-arm moiety and short-arm moiety substantially containing no endogenous gene, a human centromere, and a telomere; and collecting the human cell containing the human artificial chromosome vector from the cell population. As well as, the human cell comprises the human artificial chromosome vector.

Abstract: The object is to provide a method for producing a cyclic oligosaccharide through which a cyclic oligosaccharide can be efficiently synthesized. In addition, the object is to provide a novel cyclic oligosaccharide obtained through the production method. The method for producing a cyclic oligosaccharide includes subjecting a linear oligosaccharide, in which 5 to 10 ?-glucosamines or derivatives thereof are bonded in series via 1,4-bonds, to a liquid phase electrolysis reaction.

Abstract: Provided is an approach for achieving the expansion of a human antibody repertoire in a human antibody-producing non-human animal. Provided is a mammalian artificial chromosome vector comprising a human immunoglobulin heavy chain locus in which a D-region of a human immunoglobulin heavy chain is modified, and a human immunoglobulin light chain locus, a mammalian cell or a non-human animal comprising this mammalian artificial chromosome vector, and a method for substituting a D-region of a human immunoglobulin heavy chain with a modified sequence thereof in the production of this artificial chromosome vector.

Abstract: The present invention relates to isolated strains of Epichloë endophytes that form stable symbiotic associations with cereal grasses, particularly wheat, wherein the symbiotic associations are combinations of endophytes and host plants that are not found in nature The invention also relates to methods of identifying and/or selecting fungal endophytes that form stable symbiotic associations with wheat plants including methods of screening for fungal endophytes that form stable symbiotic associations with wheat plants, and to methods of screening for wheat plants that form stable symbiotic associations with fungal endophytes.

Abstract: Provided is a human antibody against a spike protein of coronavirus, in particular, against a protein in an extracellular region or a receptor-binding domain.

Abstract: This application provides: a non-human animal that comprises a mouse artificial chromosome comprising a human antibody heavy chain gene or gene locus, a human antibody light chain ? gene or gene locus, and/or a human antibody light chain ? gene or gene locus, and in which endogenous antibody genes or gene loci corresponding to at least 2 human antibody genes or gene loci have been knocked out, wherein the animal can be stably retained through generations and can produce human antibodies; a method for producing the non-human animal; and a method for producing human antibodies using the non-human animal.

Abstract: The present disclosure provides a composition comprising a nucleic acid delivery vehicle, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding chemokine (C-C motif) ligand 19 (CCL19), and its use thereof.

Abstract: Provided is a silyl ether-containing sulfonate salt that contains an anion represented by formula (1) and a cation. (In the formula, R1 to R4 are each independently a C1-4 alkyl group. m is an integer from 1 to 3. n is an integer from 2 to 8.

Abstract: An information processing apparatus includes a converting portion having a plurality of electrical conductors to be arranged in mutual separation and a medium arranged so as to mutually connect the plurality of electrical conductors, wherein the converting portion is the information processing apparatus to convert an input signal to an output signal. The medium includes the electrolyte and is configured to be capable of controlling an electrical conductivity of an electrically conductive path mutually electrically connecting the plurality of electrical conductors, and the medium is selected such that the electrical conductivity of the electrically conductive path changes over time with the input signal not being present.

Abstract: A technique capable of providing a user with information obtained by OCT imaging in a useful way, particularly for assisting in assessment of an embryo effectively. The image processing method includes acquiring original signal data indicating an intensity distribution of signal light from each position in three-dimensional space including a cultured embryo obtained by optical coherence tomography imaging, generating spherical coordinate data based on the original signal data, the spherical coordinate data indicating a relationship between each position in the three-dimensional space represented using spherical coordinates having an origin set inside the embryo and the intensity of the signal light from the position, and outputting the intensity distribution of the signal light as a two-dimensional map based on the spherical coordinate data using two deflection angles of the spherical coordinates as coordinate axes.

Abstract: [Problem] To provide a composition and a cell sheet which are highly effective for inhibiting fibrosis, or cells having fibrosis-inhibiting activity, which are useful in regenerative medicine. [Solution] A medium containing IC-2 or a related compound is inoculated with mesenchymal stem cells or bone marrow mononuclear cells, and the cells are cultured for a prescribed period of time while the IC-2 or related compound is maintained at a constant concentration, thereby allowing a composition and a cell sheet which are highly effective for inhibiting fibrosis, or cultured cells having fibrosis-inhibiting activity, to be obtained.

Abstract: An object of the present invention is to provide a method for producing a reversibly immortalized cell which can allow a cell into which an immortalizing gene is introduced to proliferate over a long period without damaging the chromosome of the cell, and is capable of removing the immortalizing gene, and to provide a method for obtaining a large amount of a reversibly immortalized cell that can be cloned and has stable quality. The present invention provides a method for producing a reversibly immortalized cell, comprising the steps of: introducing a chromosomally non-integrated RNA virus vector loaded with one or two or more immortalizing gene(s), selected from the group consisting of Bmi-1 gene, TERT gene, and SV40T gene, into a mammalian cell so that the immortalizing gene is expressed in the cell; and culturing the obtained cell for proliferation.

Abstract: In this application, the provided are: a Down syndrome rat model characterized in that a rat gene homologous to at least one gene present on a human chromosome 21 or fragment thereof is a trisomy and is transmittable to progeny; or a Down syndrome rat model characterized in that it comprises a human chromosome 21 or fragment thereof, or an exogenous rat chromosome or fragment thereof on which a rat gene homologous to the human chromosome 21 or fragment thereof is present, wherein at least one gene on the human chromosome 21 or fragment thereof or on the exogenous rat chromosome or fragment thereof is added to endogenous rat genes homologous to the at least gene so as to become a trisomy and to be transmittable to progeny: and a method for producing the Down syndrome rat model.

Abstract: The present invention provides a vaccinia virus which specifically grows in cancer cells and damages cancer cells and use of the virus for cancer treatment. The oncolytic vaccinia is deficient in a region consisting of 7000 to 9000 nucleotides in the genome sequence of a vaccinia virus and does not grow in normal cells, but grows specifically in cancer cells and damages cancer cells specifically.

Abstract: A vaccinia virus into which a therapeutic gene has been introduced as an exogenous gene and a therapeutic composition containing the same. The vaccinia virus contains at least one immune regulating gene as an exogenous gene.

Abstract: The present invention provides: a complex comprising a genome editing enzyme and a cell membrane-permeable peptide(CPP), wherein the CPP is fused to the genome editing enzyme; a complex comprising a genome editing enzyme, a target gene-specific nucleic acid, and a CPP, wherein the CPP is fused to the genome editing enzyme and/or the a target gene-specific nucleic acid; the complex comprising a polycationic moiety fused to the CPP, wherein the polycation moiety is statically bound to the target gene-specific nucleic acid; a genome editing method using the complex; and a kit for genome-editing, the kit including these complexes.

Abstract: This invention provides a method for producing a glycan with improved yield ratio of streocontrolled glycan. Additionally it provides the building blocks used as the sugar donor and as the sugar acceptor to implement a method for producing the glycan. It also provides a novel compound. It subjects the specific building block A of this invention to electrolytic oxidation in an aprotic organic solvent that contains an electrolyte; and subjects the specific building block B of this invention to glycosylation with the electrolytically oxidized building block A in the method for producing a glycan based on the liquid phase process.

Abstract: Provided are the following: an MWW type zeolite which has many Brønsted acid sites when in the form of a proton type and which is highly suitable as a cracking catalyst for cumene; a method for producing same; and an application of same. The present invention provides an MWW type zeolite in which the ratio (B/A) of the peak intensity (B) attributable to tetracoordinate aluminum relative to the peak intensity (A) attributable to hexacoordinate aluminum is 2 or more in 27Al MAS NMR, when measured as an ammonium type. The present invention also provides a method for producing an MWW type zeolite, the method having a step for carrying out a hydrothermal synthesis reaction in the presence of: a seed crystal of an MWW type zeolite containing no organic structure-directing agent; and a reaction mixture containing a silica source, an alumina source, an alkali source, an organic structure-directing agent, and water. The reaction mixture satisfies the following molar ratio: X/SiO2<0.

Abstract: This invention provides a vaccinia virus that induces cell fusion between infected cells and a method for producing the same. Such vaccinia virus is deprived of the K2L gene or the HA gene or functions of the K2L gene and the HA gene and is mutated to induce cell fusion between infected cells and induce cell death.